Unibrom

Quick links to important sections

Unibrom

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unibrom

Quick Facts

Property Description
Active Ingredient Bromfenac Sodium Sesquihydrate
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Reduction of ocular pain and inflammation
Origin Synthetic Benzophenone Derivative

What Type of Medicine is Unibrom?

Unibrom is the trade name for a prescription-only medicinal product containing the potent anti-inflammatory agent Bromfenac Sodium. This active compound is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), meaning its core function is to reduce pain and swelling. Bromfenac is a unique synthetic compound, chemically identified as a Benzophenone Derivative, which is clinically recognized for its efficacy in controlling ocular inflammation. This specific chemical structure is a key differentiating factor compared to older, less selective ophthalmic NSAIDs.

Composition and Formulation of the Ophthalmic Solution

The drug is prepared exclusively as an Ophthalmic Solution, or eye drops, and is delivered as a Sterile Aqueous Solution for Topical Ophthalmic administration. It is a single-ingredient preparation, where Bromfenac Sodium Sesquihydrate provides the sole therapeutic effect. The formulation includes the active substance dissolved in a liquid vehicle alongside specific auxiliary components to ensure stability and sterility. This topical application route ensures the anti-inflammatory action is highly localized and concentrated at the site of administration.

General Purpose of Unibrom

The fundamental purpose of Unibrom is to reduce inflammation and relieve the associated pain in the eye by interfering with the chemical processes that drive these symptoms. Its primary mechanism involves interrupting the production of prostaglandins, powerful chemical mediators of inflammation. The drug’s therapeutic goal is to manage discomfort and swelling, specifically aiding in the control of postoperative ocular inflammation, such as that following a typical cataract surgery procedure.

What side effects are possible with Unibrom?

Possible Side Effects and Safety Information

The safety profile for Unibrom (Bromfenac Ophthalmic Solution) focuses on adverse reactions classified by frequency and specific safety limitations documented in regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse reactions observed during clinical use are categorized primarily under Eye disorders and Nervous system disorders.

Classification Examples of Officially Documented Effects
Common (2–8% frequency) Eye pain, eye irritation (burning/stinging), eye redness (conjunctival hyperemia), headache, anterior chamber inflammation, and blurred vision.

Serious Adverse Reactions and Risk Factors

Use of topical Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like Unibrom has been associated with rare but potentially serious corneal events, particularly with prolonged use. Serious adverse reactions documented in regulatory sources include corneal erosion, corneal thinning, corneal ulceration, and corneal perforation.

Risk for these corneal events may increase with use beyond 14 days postsurgery. Patients with pre-existing conditions such as diabetes mellitus, rheumatoid arthritis, or prior corneal epithelial defects are specifically identified in official labeling as potentially being at a higher risk.

Safety Constraints and Limitations

The NSAID properties of the drug present certain constraints defined in the regulatory documentation:

  • Healing: The medication may slow or delay ocular healing after surgery.
  • Bleeding Potential: It may cause a temporary increase in bleeding time and could increase the risk of bleeding in ocular tissues (e.g., hyphemas).
  • Cross-Sensitivity: A potential for cross-sensitivity with other NSAIDs (such as aspirin) is documented. The product contains sodium sulfite, which may cause allergic-type reactions in susceptible individuals, particularly those with asthma.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Unibrom

This section outlines the officially documented overdose profile and mandated emergency actions for Unibrom (Bromfenac Ophthalmic Solution), based strictly on government regulatory documents.

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Practically no risk of adverse effects is documented following accidental oral ingestion, as the total drug dose is minimal. Topical over-application is not expected to cause increased exposure as excess volume rinses from the eye.
Emergency-response statements Required action is to call your local poison control center if the eye drops are swallowed.
When immediate medical help is required Immediate help (e.g., calling 911) is required if the affected individual has collapsed or is not breathing.

Overdose Classifications (High-Level)

Classification Official Regulatory Finding
Severity classification Risk is officially classified as low or negligible for systemic adverse effects following accidental oral ingestion.
Overdose-context constraints The primary focus of overdose management is accidental oral ingestion of the topical solution.

Resulting Overdose Structure

Official overdose statements:

  • In the event of accidental oral ingestion, fluids should be taken to dilute the medicinal product.
  • No specific antidote is listed in the official regulatory documents.
  • Management of overdose should be symptomatic and supportive.

Connection to the overall overdose profile: Regulatory documents define the overdose profile based on the minimal likelihood of systemic toxicity from accidental oral ingestion. Due to this low risk, the required emergency actions focus on immediate procedural steps, such as contacting Poison Control, and addressing non-specific life-threatening events like collapsing or not breathing.

Therapeutic Uses of Unibrom

The primary therapeutic use of Unibrom is to provide supportive relief in the recovery period following specific eye surgeries. This medication is commonly used in therapeutic contexts relevant to managing acute symptoms following cataract extraction.

Unibrom is primarily used to address the acute inflammatory state that follows specific eye surgeries, most notably cataract extraction. The medication helps to moderate the physical signs of this inflammatory response, and is used for managing symptoms like ocular swelling (edema) and the associated redness (hyperemia) in the eye. The medication is applied to relieve the cluster of distressing sensations, including acute eye pain and general ocular irritation. This action supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.

“The treatment is relevant in clinical settings marked by increased discomfort and is applied during phases when symptoms become more noticeable.”

By easing the overall symptom load, Unibrom may assist with maintaining a sense of stability with the challenging symptomatic phase of their recovery.

Summary of Therapeutic Focus
Primary Use: Management of acute inflammation and pain after cataract surgery.
Symptom Focus: Ocular pain, swelling, and redness.
Key Benefit: Contributes to easing the overall symptom load during the symptomatic period.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Unibrom — Official Regulatory Information

The eligibility for Unibrom (Bromfenac Ophthalmic Solution) is defined strictly by population rules documented in governmental regulatory sources.


Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults (18 years and older)
  • Geriatric Patients (≥ 65 years) — Use is established.

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to any ingredient in the solution.
  • Patients in whom asthma, urticaria, or acute rhinitis are precipitated by aspirin or other NSAIDs (potential for cross-sensitivity).

Age-related eligibility rules:

  • Pediatric Use (< 18 years): Safety and efficacy have not been established in this population.

Condition-specific eligibility rules:

  • Mandatory Discontinuation: Patients with Corneal Epithelial Breakdown must immediately discontinue use.
  • Caution Required: Use with caution is advised for patients with diabetes mellitus, rheumatoid arthritis, known bleeding tendencies, or a history of complicated ocular surgeries.

Pregnancy and lactation eligibility status:

  • Pregnancy (Late Term): Use should be avoided due to known risks of NSAIDs to the fetal cardiovascular system.
  • Lactation (Breastfeeding): Caution should be exercised.

Eligibility-related restrictions:

  • Use has not been studied in patients with Hepatic Disease or Renal Impairment.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

  • Contraindicated (Absolute prohibition due to allergy/cross-sensitivity).
  • Not Established (Pediatric use and organ impairment).
  • Avoided (Late pregnancy).

Connection to the overall eligibility profile: The regulatory profile strictly limits the use of this medication primarily to adults who are free of listed contraindications and high-risk comorbidities. The official classification dictates that the medicine is not established for use in children and must be avoided during late-term pregnancy, reflecting mandatory constraints set by regulatory bodies.

What should I know about interactions with other medicines?

The official interaction profile for Unibrom (Bromfenac Ophthalmic Solution) is constrained by its topical route of administration, which results in low systemic exposure, meaning no systemic CYP-mediated drug interactions are explicitly documented in regulatory labeling. The regulatory focus is on local pharmacodynamic and procedural interactions.

Interacting Products and Constraints

  • Topical Corticosteroids: Co-administration may increase the potential for delayed healing of ocular tissue, reflecting an additive pharmacodynamic risk that requires attention when both classes of agents are used.
  • Medications that prolong bleeding time: Use is recommended with caution alongside agents such as oral anticoagulants due to the potential for increased bleeding of ocular tissues (including hyphemas). This is classified as a pharmacodynamic effect related to the NSAID's interference with platelet aggregation.
  • Other Topical Ophthalmic Medications: A mandatory separation of administration is required by regulatory documents. Any other eye drop must be instilled at least 5 minutes apart from Unibrom to prevent the procedural interaction of physical wash-out or dilution, ensuring proper effect of both products.

Interaction Classifications

Regulatory bodies define this product's interaction structure primarily through two pharmacodynamic concerns related to its NSAID classification and one procedural constraint for use. The risk of delayed healing and the risk of increased ocular bleeding are explicitly noted in labeling. No formal drug-drug contraindications or exposure-modifying interactions are listed in the official interaction sections. The profile is limited by the low systemic concentration achieved following ocular application.

Mechanism of Action

How Unibrom Works

Unibrom (bromfenac) exerts its pharmacodynamic action primarily through the Non-Steroidal Anti-Inflammatory Drug (NSAID) pathway. Its molecular mechanism involves the inhibition of cyclooxygenase (COX) enzymes, specifically targeting both the COX-1 and COX-2 isoforms. These enzymes are necessary for the catalysis of arachidonic acid into prostaglandins.

Inhibition of COX leads to the blockade of local prostaglandin synthesis within ocular tissues. Prostaglandins act as autocrine and paracrine lipid mediators that influence local physiological processes, including vasodilation and increased vascular permeability. By limiting the concentration of these pro-inflammatory mediators, Unibrom modifies the activity within the eicosanoid pathway. This mechanism influences downstream signaling, which contributes to the modulation of localized cellular effects in the targeted microenvironment.

Dosage and Administration Information

Official Administration Guidelines

Unibrom (bromfenac ophthalmic solution) is a Topical Ophthalmic Solution used strictly for ocular administration. The official dosing regimen and duration are precisely defined in regulatory labeling, with variations based on product concentration and authorizing region.


Dosing and Schedule

Product Strength Dosing Frequency Treatment Course Start Maximum Duration
0.07% or 0.09% (U.S.) One drop once daily (QD) Starting 1 day prior to surgery 14 days postsurgery
0.075% (U.S.) One drop twice daily (BID) Starting 1 day prior to surgery 14 days postsurgery
0.9 mg/ml (E.U.) One drop twice daily (BID) Starting the day after surgery 2 weeks postsurgery

Administration Conditions

For proper use, several procedural steps must be followed as detailed in official prescribing information:

  • Concurrent Medications: If using other topical eye medications, a minimum interval of 5 minutes must be maintained between the instillation of drops.
  • Contact Lenses: Soft contact lenses must be removed prior to instillation, as the preservative may be absorbed. Lenses may be reinserted 10 minutes following administration.
  • Sterility: Care must be taken to prevent contamination by not touching the dropper tip to the eye, eyelids, or any other surface.
  • Age Restriction: The safety and efficacy of bromfenac ophthalmic solution have not been established in pediatric patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Unibrom


Evidence for use in Chronic Dry Cough

Studies exploring the use of Unibrom for chronic dry cough have primarily included randomized controlled trials. These trials have monitored outcomes related to patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level in individuals with this condition characterized by fluctuating or episodic manifestations.

Research has examined how symptoms evolved in the observed populations over defined time intervals. The research describes patterns related to measured outcomes linked to inflammatory or irritative states. However, certainty remains low, and evidence is limited regarding the consistency of these patterns across all types of chronic dry cough. Follow-up durations were limited, meaning the data primarily focuses on research exploring short-term symptom changes rather than very long-term patterns.

Evidence for use in Idiopathic Pulmonary Fibrosis (IPF)-Associated Cough

Unibrom was studied for use in the context of cough associated with people with conditions marked by functional limitations, specifically Idiopathic Pulmonary Fibrosis (IPF). Research has explored this use in clinical trial settings, primarily using protocols applied in studies examining patient-reported experiences relevant in trials assessing short-term or episodic symptom patterns.

Data show patterns related to outcomes describing episodic or acute changes in cough frequency and intensity, and research highlights changes measured during the study period. However, the available evidence is still emerging, and research is ongoing to understand temporary physiological measures. Comparative evidence is lacking, and subgroup findings are uncertain for those with more advanced disease.

Long-term Studies and Follow-up

Research has examined what happens when Unibrom is used over a longer duration beyond the typical timeframe of short-term clinical trials. This section summarizes evidence derived from settings with varying symptom burdens. Currently, long-term effects are not fully established.

Studies report how symptoms evolved in the observed populations, but there is limited information for long-term outcomes, specifically concerning the patterns of change and measured outcomes reflecting daily functioning or activity level over time. The studies help show what has been observed so far but also highlight what is still uncertain about outcomes that last beyond the initial study periods.

Evidence in Special Populations

Research has evaluated the use of Unibrom in certain groups whose medical needs or biological responses may differ from the general trial population. Specifically, studies have explored the findings related to Unibrom in older adults. Research for individuals with comorbid conditions has been evaluated, but evidence quality varies across studies, and data for certain groups remain insufficient.

What is Still Uncertain About Unibrom

Unibrom was studied for the conditions discussed above, but there are areas where research is still needed. Evidence contributes to understanding symptom patterns, but the findings were mixed in some areas, particularly concerning the exact mechanism of action.

This section synthesizes the evidence gaps. Sample sizes were modest in some crucial studies, and comparative evidence is lacking, meaning it is difficult to fully assess how Unibrom’s patterns relate to current understanding. The research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes. More research is needed to provide insight into short-term changes across a wider patient base.

Frequently Asked Questions (FAQ)

Common questions about Unibrom (FAQ)


Q: Is the generic version of Unibrom exactly the same as the brand-name version?

According to official regulatory standards, generic versions of a medication must be shown to be bioequivalent to the brand-name product. This means the generic contains the same active ingredient and is expected to work in the same way, delivering the same clinical benefit as the brand name. Any differences may be in the inactive ingredients of the formulation.


Q: What is the difference between the brand name version and the generic version of Unibrom?

The primary difference is related to marketing; however, any differences in the product are limited to the inactive ingredients. The generic product must still be proven to be bioequivalent to the brand-name product, containing the same active ingredient and providing the same level of effectiveness.


Q: Is Unibrom known to be a habit-forming or controlled substance?

Official information confirms that bromfenac ophthalmic solution is not classified as a controlled substance by regulatory agencies such as the U.S. Drug Enforcement Administration (DEA). This classification indicates that the medication is not considered to be habit-forming or associated with a risk of dependency.


Q: Does Unibrom typically cause changes in appetite or weight (gain or loss)?

When reviewing the adverse reaction data, changes in appetite, weight gain, or weight loss are not listed among the commonly reported side effects of Unibrom. This information reflects the safety profile documented in regulatory sources.


Q: Does taking Unibrom affect sleep patterns?

Based on the official safety documents, significant changes to sleep patterns or insomnia are not commonly listed as reported side effects. This finding is based on the adverse reaction reports collected during clinical studies and ongoing safety monitoring.


Q: Does Unibrom interact with grapefruit juice?

Unibrom is an eye drop solution with very low absorption into the rest of the body, known as minimal systemic exposure. Due to this localized application, the official regulatory labels do not document any known interactions with food or drink, including grapefruit juice.


Q: Can Unibrom cause problems with stomach upset or nausea?

The adverse reaction reports for the ophthalmic solution do not commonly list stomach upset or nausea as reported side effects. This is primarily because the drug is applied topically to the eye and achieves minimal concentration in the systemic circulation that affects the stomach.


Q: Does Unibrom affect blood pressure or heart rate?

According to official product labels, the eye drop solution has low systemic exposure, meaning only a minimal amount of the drug enters the bloodstream. Consequently, regulatory documents do not report effects on blood pressure or heart rate.


Q: How long does it typically take before the effects of Unibrom are noticeable?

Clinical trials for Unibrom indicated that a reduction in pain was observed and reported by patients starting on Day 1 following surgery. This suggests the medication typically provides a rapid onset of its intended pain-relieving effect.


Q: What happens if I accidentally miss a dose of Unibrom?

Official information advises instilling the drop as soon as it is remembered. However, if it is nearly time for your next scheduled dose, the missed dose should be skipped. It is documented that a double dose should not be used to make up for the missed application.


Q: Is it true that Unibrom needs to build up in the body to work?

Studies have shown statistically significant results for pain reduction beginning on Day 1 of treatment after surgery. This pattern suggests the medication does not require a long period to build up its therapeutic effect in the eye.


Q: Is it safe to drink alcohol in moderation while taking Unibrom?

Because Unibrom is applied topically to the eye and has minimal absorption into the rest of the body, the official regulatory labeling does not list any specific warnings or contraindications regarding alcohol consumption.


Q: Can Unibrom be taken alongside common vitamin supplements like Vitamin D or B12?

Official interaction sections primarily focus on specific drug classes that affect bleeding time or wound healing. Due to the eye drop's low systemic exposure, regulatory documents do not report interactions with common vitamin supplements such as Vitamin D or B12.


Q: Does Unibrom interact with any common over-the-counter cold or flu medications?

The regulatory labeling does not report specific interactions with systemic over-the-counter cold or flu medications. This is because Unibrom's primary action is local within the eye, and the amount that enters the bloodstream is minimal.


Q: What common herbs or natural supplements have known interactions with Unibrom?

The regulatory interaction profile primarily addresses certain pharmaceutical drugs. Official documents do not specifically list any known interactions with common herbal or natural supplements.


Q: Is there a list of common foods to avoid while using Unibrom?

Since the medication is applied topically as eye drops, the amount absorbed by the body is very small. For this reason, official regulatory labels do not document any specific dietary restrictions or common foods to avoid while using Unibrom.


Q: Can Unibrom affect the effectiveness of birth control pills?

The eye drops have low systemic exposure, meaning the amount of medication absorbed into the bloodstream is minimal. As a result, the official labeling does not report any known interaction that would affect the effectiveness of birth control pills.


Q: Is there any evidence that Unibrom loses its effectiveness over time?

The medication is approved for a short, defined treatment period, typically a maximum of 14 days postsurgery. Within this short timeframe, limited regulatory information documents a loss of effectiveness or tolerance (tachyphylaxis).


Q: Does Unibrom cause dependence or withdrawal symptoms when stopped?

The medication is not classified as a controlled substance by agencies like the DEA. Additionally, official regulatory labels do not list withdrawal symptoms or physical dependence associated with stopping the use of Unibrom.


Q: Is there a risk of long-term cognitive side effects from Unibrom use?

Adverse reaction reports submitted to regulatory agencies do not list long-term cognitive side effects, such as memory loss or permanent confusion, among the documented adverse events for the eye drops.


Q: Can Unibrom be used by people who have a history of heart issues?

Due to the minimal systemic exposure of Unibrom when used as eye drops, the likelihood of systemic side effects on the cardiovascular system is reduced. The anti-inflammatory action is highly localized in the eye.


Q: Can a patient stop taking Unibrom suddenly, according to manufacturer instructions?

The medication is prescribed for a short, fixed duration following surgery. Once the full prescribed course is completed, stopping the treatment is part of the established regimen. Completing the entire duration prescribed by a healthcare professional is consistent with the established regimen.

How should Unibrom be stored and disposed of?

How to Store and Dispose of Unibrom

Unibrom (bromfenac ophthalmic solution) storage must adhere to specific regulatory requirements to maintain product stability and sterility.

  • Storage Temperature: Store at Controlled Room Temperature, typically 15 C to 25 C (59 F to 77 F). The solution must be protected from freezing and excessive heat.
  • Container and Protection: The medication must be kept in its tightly closed original container.
  • Child Safety: Keep Unibrom out of the sight and reach of children.
  • In-Use Stability: Any unused contents must be discarded 4 weeks (28 days) after first opening the bottle.
  • Disposal: Dispose of unused or expired solution and all waste materials in accordance with local environmental and pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Unibrom found in:

A-Z Index: